Workflow
Fetal hemoglobin induction
icon
Search documents
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Globenewswireยท 2025-07-29 10:45
Core Insights - Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD) [2][3] Efficacy Data - The mean absolute fetal hemoglobin (HbF) increased by 8.6% from a baseline of 7.6% to 16.2% after 12 weeks of treatment, with 7 out of 16 patients achieving HbF levels greater than 20% [4][10] - The proportion of F-cells increased from 34% at baseline to 67% at 12 weeks, indicating pan-cellular induction of HbF [4][10] - Key markers of hemolysis showed meaningful improvements, including a mean increase in total hemoglobin of 0.9 g/dL, from 7.8 g/dL to 8.7 g/dL [10] - A trend of reduced vaso-occlusive crisis (VOC) rates was observed, with 50% of patients reporting no VOCs during the treatment period [10] Safety Profile - Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) reported, and all treatment-related adverse events (AEs) were Grade 1 [3][10] - The safety profile observed in the 12 mg dose cohort was consistent with previously reported data [10] Company Overview - Fulcrum Therapeutics is focused on developing small molecules for genetically defined rare diseases, with pociredir as its lead clinical program aimed at increasing HbF expression for SCD treatment [8][9]
Fulcrum Therapeutics(FULC) - 2025 Q1 - Earnings Call Transcript
2025-05-01 12:00
Financial Data and Key Metrics Changes - Research and development expenses decreased to $13.4 million in Q1 2025 from $19.8 million in Q1 2024, a reduction of $6.4 million attributed to the discontinuation of the losmapimod program and reimbursement under the Sanofi collaboration [10] - General and administrative expenses fell to $7 million in Q1 2025 from $10.1 million in Q1 2024, a decrease of $3.1 million primarily due to reduced employee compensation costs following workforce reductions [11] - Net loss improved to $17.7 million in Q1 2025 compared to a net loss of $26.9 million in Q1 2024 [11] - Cash, cash equivalents, and marketable securities decreased to $226.6 million as of March 31, 2025, from $241 million at the end of 2024, a decrease of $14.4 million mainly due to cash used for operating activities [11][12] Business Line Data and Key Metrics Changes - The lead program, coceridere, is currently enrolling in a phase 1b trial called PIONEER for sickle cell disease, with 16 patients enrolled in the 12 mg cohort [4][5] - The data monitoring committee recommended continuing the study and initiating the 20 mg cohort, which is now underway [5] - The company plans to report data from the 20 mg cohort by the end of 2025 [5] Market Data and Key Metrics Changes - Approximately 100,000 people in the US and 4.4 million people worldwide are affected by sickle cell disease [4] - Evidence suggests that even modest increases in fetal hemoglobin correlate with reduced disease severity, with a 1% increase in fetal hemoglobin leading to a 4% to 8% reduction in vaso-occlusive crises [7] Company Strategy and Development Direction - The company believes inducing fetal hemoglobin is the optimal strategy for treating sickle cell disease, supported by recent data analysis and approved gene therapies [6] - Plans to submit an IND for Diamond Blackfan anemia in Q4 2025, indicating a focus on expanding treatment options for inherited hematological conditions [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in 2025 and the upcoming data releases from the PIONEER trial [13] - The company expects existing cash reserves to fund operations into at least 2027, indicating a stable financial outlook [12] Other Important Information - The company has two abstracts accepted for presentation at the upcoming European Hematology Association meeting, highlighting ongoing research efforts [8] Q&A Session Summary Question: Data expectations from the twelve milligram cohort of PIONEER - Management confirmed that they will provide hematological parameters, including markers of hemolysis, and data for all 16 patients after a three-month treatment phase [15][16] Question: Observed dosing data and adherence - The company utilizes an AI tool to track adherence, reporting over 90% adherence to the once-daily oral regimen [19][21] Question: Baseline fetal hemoglobin levels and patient demographics - Management acknowledged that the baseline fetal hemoglobin levels were higher than expected, indicating a representative sample of the broader demographic [25][26] Question: Win criteria from the twelve-week data - Any increase in fetal hemoglobin is considered beneficial, with a clinically meaningful reduction in vaso-occlusive crises expected from increases in fetal hemoglobin [34][35] Question: Impact of FDA shifts on development - The company plans to interact with the FDA at the end of the phase 1b study to gauge regulatory perspectives on endpoint selection and development timelines [53][55]